Basilea Presents Research Data at ICAAC on Novel Antibiotic Addressing the Emerging Threat from Multi-resistant Gram-negative Bacteria
BASEL, Switzerland, 17th September 2007 - Multi-resistant Gram-negative bacteria have been appearing with increasing frequency around the world. Basilea's antibiotic BAL30376 demonstrates a broad-spectrum in-vitro activity targeting multi-resistant Gram-negative bacteria.
Basilea Pharmaceutica's Head of Biology Prof. Malcolm Page, presented in vitro data today at the Poster Review Session of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The research results demonstrate that BAL30376 has potent in vitro activity against a broad spectrum of Gram-negative bacteria.
In vitro antibacterial activity data presented by Bowker et al., Hujer et al. and Page et al. showed that the minimal inhibitory concentrations of BAL30376 for many strains of beta-lactam-resistant Gram-negative bacteria were lower than those of comparator antibiotics. The in vitro antimicrobial spectrum of BAL30376 included strains of Acinetobacter, Pseudomonas aeruginosa and Klebsiella pneumoniae that were not susceptible to any of the other antibiotics that were tested. The promising in vitro activity of BAL30376 translated into its ability to provide protection in an in vivo model of bacterial sepsis.
Multi-resistant Gram-negative bacteria have been appearing with increasing frequency in hospitals around the world. Such organisms are now considered by organizations such as the Infectious Diseases Society of America, to pose significant threats to successful therapy of life-threatening infections. In particular, Acinetobacter, Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae have been identified as organisms for which there is an urgent need for new antimicrobial agents.
"BAL30376 derives from Basilea's expertise in antibacterial drug discovery specifically in the area of beta-lactam chemistry. This unique combination targets pan-resistant Gram-negative bacteria for which no treatment is available and strengthens the position of Basilea as a leader in anti-infectives", said Prof. Jutta Heim, Basilea's Chief Scientific Officer.
About Basilea Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX:BSLN). Basilea is currently focused on the research, development and commercialization of new antibacterial, antifungal and dermatology drugs.
Data on BAL30376 and related compounds presented at ICAAC 2007 Novel mono- and bi-cyclic monobactams as potent inhibitors of class C b-lactamases. Poster #F1-310 - Gaucher B, Dantier C, Desarbre E, Page M G P (Basilea Pharmaceutica Ltd, Basel Switzerland)
Activity of monobactam/b-lactamase inhibitor combinations against b-lactam-resistant Gram-negative bacteria. Poster #F1-311 - Page M G P, Desarbre E, Geier C, Hofer B (Basilea Pharmaceutica Ltd, Basel Switzerland)
Activity of BAL30376 against Gram-negative bacteria. Poster #F1-312 - Page M G P, Desarbre E, Geier C, Hofer B (Basilea Pharmaceutica Ltd, Basel Switzerland)
In vitro potency of BAL30376 against Gram-negative bacilli (GNB). Poster #F1-313 Bowker K, Noel AR, Macgowan A P, Walsh T R (Southmead Hospital, Bristol, UK)
A monobactam plus double b-lactamase inhibitor combination designed to overcome multiple resistance in Gram-negative bacilli: proof of concept in an in vitro pharmacokinetic model. Poster #F1-314 Bowker K, Noel AR, Macgowan A P, Walsh T R (Southmead Hospital, Bristol, UK)
Efficacy of BAL30376 in a murine model of Gram-negative sepsis. Poster #F1-315 Schmitt-Hoffmann A, Desarbre E, Gaucher B, Gebhardt K, Page MGP (Basilea Pharmaceutica Ltd, Basel, Switzerland)
Activity of BAL30376 against multidrug resistant (MDR) Klebsiella and Acinetobacter sp. Poster #F1-333a Hujer A M, Desarbre E, Endimiami A , Paterson D L , Page M G P , Bonomo R A  (VA Med. Ctr., Cleveland, USA; Basilea Pharmaceutica Ltd, Basel, Switzerland; Univ. of Pittsburgh, Pittsburgh, USA)
Antimicrobial activity of novel monobactams. Poster #F1-351 Desarbre E, De Fontages A, Page MGP, Richalet F, Roussel P (Basilea Pharmaceutica Ltd, Basel, Switzerland).
For abstracts of all posters please log on to www.icaac.org
Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
+----------------------------------------------------------+ | General Information | Investor Relations | |-------------------------+--------------------------------| | email@example.com | Dr. Barbara Zink | | | firstname.lastname@example.org | +----------------------------------------------------------+
Posted: September 2007